Sponsors (104)
The bill tightens control, reporting, and sentencing around xylazine to improve enforcement and public-health surveillance, while risking expanded criminal penalties, compliance costs, and disruptions or diversion risks for legitimate veterinary, research, and clinical uses.
Law enforcement, prosecutors, and policymakers gain clearer statutory definitions, an explicit scheduling placement, and better data/reporting on xylazine, improving investigators' ability to detect, prosecute, and target trafficking and diversion.
Hospitals, clinicians, and public-health agencies get clearer legal definitions, surveillance data, and clinical guidance that improve detection, reporting, and treatment protocols for xylazine exposure.
People exposed to illicit xylazine face reduced availability of unregulated/unscheduled xylazine-containing products because the drug is explicitly placed under Schedule III, which should curb illicit supply.
People who possess or use xylazine (including trace contamination in mixtures) face expanded criminal exposure and increased risk of arrest or prosecution as xylazine is defined and scheduled.
Stricter/statutorily specific penalties for xylazine offenses are likely to increase incarceration rates and costs and will disproportionately harm communities already overrepresented in the criminal system.
Veterinarians, researchers, and patients relying on legitimate xylazine-containing veterinary or research products may face reduced access, supply disruptions, or delays obtaining controlled supplies.
Based on analysis of 7 sections of legislative text.
Introduced February 12, 2025 by James Varni Panetta · Last progress February 12, 2025
Adds xylazine to Schedule III of the Controlled Substances Act, defines the term for statutory use, and creates special possession and treatment rules for certain animal-related users and sites. The bill delays some Schedule III regulatory requirements for xylazine, prevents immediate capital-security upgrades for existing manufacturers, directs DEA and FDA to expedite necessary applications, requires the Sentencing Commission to review penalties for xylazine-related offenses, and mandates two federal reports to Congress on illicit xylazine use and trafficking. Overall, the measure focuses on bringing xylazine under federal controlled-substance controls while phasing in regulatory duties to limit sudden disruption for manufacturers, animal-care facilities, and practitioners; it also seeks more information and sentencing adjustments to address public-health and enforcement concerns.